StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Elrexfio (elranatamab by Quarter

Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — U.S. reported YoY (%) (%)

QuarterlyAnnual

Pfizer Elrexfio (elranatamab: -15.0% in Q2 2026, down 111.0 pts from a year earlier.

Latest, Q2 2026
-15.0%
Period ended Jun 28, 2026
Change on a year earlier
-111.0 pts
96.0% in Q2 2025
History
5 quarters
Since Q2 2025
Sources
5
Documents cited below

Where the Q2 2026 figure comes from

“|| Elrexfio | 89 | 85 | 4% | 5% | 30 | 35 | (15%) | 59 | 50 | 17% | 18%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedElrexfio (elranatamab — BCMA bispecific for multiple myeloma) — U.S. reported YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 2026-15.0%-111.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202615.0%–Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202526.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202540.0%–Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202596.0%–Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗

Cite this data

StockData. (2026). Pfizer Elrexfio (elranatamab (%), quarterly Q2 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/elrexfio-yoy-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.